BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Structure Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Structure Therapeutics's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07654361-177@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:aleniglipron: Phase 3 readout est. (NCT07654361)
DESCRIPTION:aleniglipron\, phase 3\, Obesity.\nStudy: Efficacy and Safety o
 f Aleniglipron in Participants With Obesity or Overweight With a Weight-Re
 lated Comorbidity (ACCOMPLISH-1)\nEstimated primary completion: September 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/aleniglipron#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076543
 61
URL:https://assetmemo.bio/drug/aleniglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654374-177@assetmemo.bio
DTSTAMP:20261121T005417Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:aleniglipron: Phase 3 readout est. (NCT07654374)
DESCRIPTION:aleniglipron\, phase 3\, Obesity.\nStudy: A Study of Aleniglipr
 on in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCO
 MPLISH-2)\nEstimated primary completion: September 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/aleniglipron#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07654374
URL:https://assetmemo.bio/drug/aleniglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
